Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675570 | 1.00 | TYMS (0.36) | TYMSPOLB | |
| SCHEMBL14979297 | 1.00 | TYMS (0.36) | TYMSPOLB | |
| SCHEMBL16086184 | 0.90 | TYMS (0.38) | TYMSPOLB | |
| SCHEMBL16681939 | 0.87 | HDAC1 (0.36) | TYMS | |
| SCHEMBL18643571 | 0.87 | HDAC1 (0.36) | TYMS | |
| SCHEMBL18643293 | 0.87 | TYMS (0.35) | TYMS | |
| SCHEMBL16681938 | 0.87 | TYMS (0.35) | TYMS | |
| SCHEMBL18643292 | 0.87 | TYMS (0.35) | TYMS | |
| SCHEMBL16681935 | 0.87 | TYMS (0.34) | TYMS | |
| SCHEMBL18643572 | 0.87 | TYMS (0.34) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073683-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2017-03-16 | — | — | US | disclosed |
| US-9540650-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2015-04-30 | — | — | US | disclosed |
| EP-2781599-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | Riken (JP) | 2014-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TARBP1, DNTT, FABP1 | TYMS 558/4885POLB 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.